{
    "title": "114_hr5549",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medical Marijuana Research Act of \n2016''.\n\nSEC. 2. PRODUCTION AND SUPPLY.\n\n    (a) In General.--The Secretary of Health and Human Services--\n            (1) until the date on which the Secretary determines that \n        manufacturers and distributors (other than the Federal \n        Government) can ensure a sufficient supply of marijuana for \n        qualified medical marijuana researchers, shall--\n                    (A) continue to produce marijuana through the \n                National Institute on Drug Abuse (NIDA) Drug Supply \n                Program; and\n                    (B) offer for sale immature marijuana plants and \n                the seeds of marijuana--\n                            (i) to all qualified medical marijuana \n                        researchers who submit a request for such \n                        plants or seeds to engage in research pursuant \n                        to the section 303(f)(3) of the Controlled \n                        Substances Act, as amended by section 3; and\n                            (ii) in quantities sufficient to produce an \n                        adequate supply of marijuana for such research; \n                        and\n            (2) beyond the date specified in paragraph (1), may, at the \n        Secretary's discretion, continue to so produce and supply \n        marijuana.\n    (b) Requirement To Verify Registration.--Before supplying marijuana \nto any person through the National Institute on Drug Abuse Drug Supply \nProgram, the Secretary of Health and Human Services shall--\n            (1) require the person to submit documentation \n        demonstrating that the person is a qualified medical marijuana \n        researcher seeking to conduct research pursuant to the section \n        303(f)(3) of the Controlled Substances Act, as amended by \n        section 3; and\n            (2) not later than 30 days after receipt of such \n        documentation, review such documentation and verify that the \n        marijuana will be used for such research.\n    (c) Guidelines on Production.--The Commissioner of Food and Drugs, \nin consultation with the Director of the National Institute on Drug \nAbuse, shall--\n            (1) not later than 180 days after the date of enactment of \n        this Act, issue guidelines on the production of marijuana by \n        qualified medical marijuana researchers pursuant to subsection \n        (a)(1)(B); and\n            (2) encourage researchers and manufacturers that are \n        authorized to produce or manufacture marijuana pursuant to \n        section 303 of the Controlled Substances Act (21 U.S.C. 823), \n        as amended by this Act, to comply with such guidelines to the \n        extent applicable.\n    (d) Definition.--In this section:\n            (1) The term ``immature marijuana plant'' means a marijuana \n        plant with no observable flowers or buds.\n            (2) The term ``qualified medical marijuana researcher'' \n        means a researcher who is registered to conduct research with \n        marijuana under section 303(f)(3) of the Controlled Substances \n        Act, as amended by section 3.\n\nSEC. 3. FACILITATING MARIJUANA RESEARCH.\n\n    (a) In General.--Section 303(f) of the Controlled Substances Act \n(21 U.S.C. 823(f)) is amended--\n            (1) by redesignating paragraphs (1) through (5) as \n        subparagraphs (A) through (E), respectively;\n            (2) by striking ``(f) The Attorney General'' and inserting \n        ``(f)(1) The Attorney General'';\n            (3) by striking ``Registration applications'' and inserting \n        the following:\n    ``(2) Registration applications'';\n            (4) in paragraph (2), as so designated, by striking \n        ``schedule I'' each place that term appears and inserting \n        ``schedule I, except marijuana,'';\n            (5) by striking ``Article 7'' and inserting the following:\n    ``(4) Article 7''; and\n            (6) by inserting before paragraph (4), as so designated, \n        the following:\n    ``(3)(A) The Attorney General shall register a practitioner to \nconduct research with marijuana if--\n            ``(i) the applicant is authorized to dispense, or conduct \n        research with respect to, controlled substances in schedules \n        II, III, IV, and V under the laws of the State in which the \n        applicant practices;\n            ``(ii) the applicant's research protocol--\n                    ``(I) has been reviewed and allowed by--\n                            ``(aa) the Secretary under section 505(i) \n                        of the Federal Food, Drug, and Cosmetic Act (21 \n                        U.S.C. 355(i)); or\n                            ``(bb) the National Institutes of Health or \n                        another Federal agency that funds scientific \n                        research; or\n                    ``(II) in the case of nonhuman research that is not \n                federally funded, has been voluntarily submitted by the \n                applicant to, and approved by, the National Institutes \n                of Health; and\n            ``(iii) the applicant has demonstrated that there are \n        effective procedures in place to adequately safeguard against \n        diversion of the marijuana from legitimate medical or \n        scientific use, in accordance with subparagraph (E).\n    ``(B) The Attorney General shall grant an application for \nregistration under this paragraph unless the Attorney General \ndetermines that the issuance of the registration would be inconsistent \nwith the public interest. In determining the public interest, the \nfollowing factors shall be considered:\n            ``(i) The applicant's experience in dispensing, or \n        conducting research with respect to, controlled substances.\n            ``(ii) The applicant's conviction record under Federal or \n        State laws relating to the manufacture, distribution, or \n        dispensing of controlled substances.\n            ``(iii) Compliance with applicable State, Federal, or local \n        laws relating to controlled substances.\n            ``(iv) Such other conduct by the applicant that may \n        threaten the public health and safety.\n    ``(C) Not later than 90 days after the date of enactment of the \nMedical Marijuana Research Act of 2016, for purposes of subparagraph \n(A)(ii)(II), the National Institutes of Health shall establish a \nprocess that--\n            ``(i) allows a researcher to voluntarily submit the \n        research protocol of the researcher for review and approval; \n        and\n            ``(ii) provides a researcher described in clause (i) with a \n        decision not less than 30 days after the date on which the \n        research protocol is submitted.\n    ``(D)(i) Not later than 60 days after the date on which the \nAttorney General receives a complete application for registration under \nthis paragraph, the Attorney General shall approve or deny the \napplication.\n    ``(ii) For purposes of clause (i), an application shall be deemed \ncomplete when the applicant has submitted documentation showing that \nthe requirements under subparagraph (A) are satisfied.\n    ``(E)(i) A researcher registered under this paragraph shall store \nmarijuana to be used in research in a securely locked, substantially \nconstructed cabinet.\n    ``(ii) Except as provided in clause (i), any security measures \nrequired by the Attorney General for practitioners conducting research \nwith marijuana pursuant to a registration under this paragraph shall be \nconsistent with the security measures for practitioners conducting \nresearch on other controlled substances in schedule II that have a \nsimilar risk of diversion and abuse.\n    ``(F)(i) If the Attorney General grants an application for \nregistration under this paragraph, the applicant may amend or \nsupplement the research protocol without reapplying if the applicant \ndoes not--\n            ``(I) change the type of drug, the source of the drug, or \n        the conditions under which the drug is stored, tracked, or \n        administered; or\n            ``(II) otherwise increase the risk of diversion.\n    ``(ii) If an applicant amends or supplements the research protocol \nor initiates research on a new research protocol under clause (i), the \napplicant shall, in order to renew the registration under this \nparagraph, provide notice to the Attorney General of the amended or \nsupplemented research protocol or any new research protocol in the \napplicant's renewal materials.\n    ``(iii)(I) If an applicant amends or supplements a research \nprotocol and the amendment or supplement involves a change to the type \nof drug, the source of the drug, or conditions under which the drug is \nstored, tracked, or administered or otherwise increases the risk of \ndiversion, the applicant shall provide notice to the Attorney General \nnot later than 30 days before proceeding on such amended or \nsupplemental research or new research protocol, as the case may be.\n    ``(II) If the Attorney General does not object during the 30-day \nperiod following a notification under subclause (I), the applicant may \nproceed with the amended or supplemental research or new research \nprotocol.\n    ``(iv) The Attorney General may object to an amended or \nsupplemental protocol or a new research protocol under clause (i) or \n(iii) only if additional security measures are needed to safeguard \nagainst diversion or abuse.\n    ``(G) If marijuana or a compound of marijuana is listed on a \nschedule other than schedule I, the provisions of paragraphs (1), (2), \nand (4) that apply to research with a controlled substance in the \napplicable schedule shall apply to research with marijuana or that \ncompound, as applicable, in lieu of the provisions of subparagraphs (A) \nthrough (G) of this paragraph.''.\n    (b) Conforming Amendment.--Section 102(16) of the Controlled \nSubstances Act (21 U.S.C. 802(16)) is amended by inserting ``or \n`marijuana''' after ``The term `marihuana'''.\n\nSEC. 4. MANUFACTURE AND DISTRIBUTION OF MARIJUANA FOR USE IN \n              LEGITIMATE, MEDICAL RESEARCH.\n\n    Section 303 of the Controlled Substances Act (21 U.S.C. 823), as \namended by section 3, is further amended by adding at the end the \nfollowing:\n    ``(k) Registration of Persons To Manufacture and Distribute \nMarijuana for Use in Legitimate, Medical Research.--\n            ``(1) Registration of manufacturers.--Beginning not later \n        than the day that is 1 year after the date of enactment of the \n        Medical Marijuana Research Act of 2016, the Attorney General \n        shall register an applicant to manufacture marijuana to the \n        extent the marijuana will be used exclusively by qualified \n        medical marijuana researchers for research pursuant to \n        subsection (f)(3), unless the Attorney General determines that \n        the issuance of such registration is inconsistent with the \n        public interest. In determining the public interest, the \n        Attorney General shall--\n                    ``(A) take into consideration--\n                            ``(i) maintenance of effective controls \n                        against diversion of marijuana and any \n                        controlled substance compounded therefrom into \n                        other than legitimate medical, scientific, or \n                        research channels;\n                            ``(ii) compliance with applicable State and \n                        local law; and\n                            ``(iii) prior conviction record of the \n                        applicant under Federal or State laws relating \n                        to the manufacture, distribution, or dispensing \n                        of such substances; and\n                    ``(B) not take into consideration any factors other \n                than the factors listed in subparagraph (A).\n            ``(2) Registration of distributors.--Beginning not later \n        than the day that is 1 year after the date of enactment of the \n        Medical Marijuana Research Act of 2016, the Attorney General \n        shall register an applicant to distribute marijuana that is \n        intended to be used exclusively by qualified medical marijuana \n        researchers for research pursuant to subsection (f)(3), unless \n        the Attorney General determines that the issuance of such \n        registration is inconsistent with the public interest. In \n        determining the public interest, the Attorney General shall--\n                    ``(A) take into consideration--\n                            ``(i) maintenance of effective controls \n                        against diversion of marijuana and any \n                        controlled substance compounded therefrom into \n                        other than legitimate medical, scientific, or \n                        research channels;\n                            ``(ii) compliance with applicable State and \n                        local law;\n                            ``(iii) prior conviction record of the \n                        applicant under Federal or State laws relating \n                        to the manufacture, distribution, or dispensing \n                        of such substances; and\n                            ``(iv) past experience in the distribution \n                        of controlled substances, and the existence in \n                        the establishment of effective controls against \n                        diversion; and\n                    ``(B) not take into consideration any factors other \n                than the factors listed in subparagraph (A).\n            ``(3) No limit on number of manufacturers and \n        distributors.--Notwithstanding any other provision of law, the \n        Attorney General shall not impose or implement any limit on the \n        number of persons eligible to be registered to manufacture or \n        distribute marijuana pursuant to paragraph (1) or (2).\n            ``(4) Requirement to verify use for legitimate, medical \n        research.--As a condition on registration under this section to \n        manufacture or distribute marijuana, the Attorney General shall \n        require the registrant--\n                    ``(A) to require any person to whom the marijuana \n                will be supplied to submit documentation demonstrating \n                that the marijuana will be used exclusively by \n                qualified medical marijuana researchers for research \n                pursuant to subsection (f)(3); and\n                    ``(B) not later than 30 days after receipt of such \n                documentation, and before supplying the marijuana to \n                such person, to review such documentation and verify \n                that the marijuana will be so used.\n            ``(5) Timing.--Not later than 30 days after receipt of a \n        request for registration under this subsection to manufacture \n        or distribute marijuana, the Attorney General shall--\n                    ``(A) grant or deny the request; and\n                    ``(B) in the case of a denial, provide a written \n                explanation of the basis for the denial.\n            ``(6) Definition.--For purposes of this subsection, the \n        term `qualified medical marijuana researcher' means a \n        researcher who is registered to conduct research with marijuana \n        under subsection (f)(3).''.\n\nSEC. 5. TERMINATION OF INTERDISCIPLINARY REVIEW PROCESS FOR NON-NIH-\n              FUNDED RESEARCHERS.\n\n    The Secretary of Health and Human Services may not--\n            (1) reinstate the Public Health Service interdisciplinary \n        review process described in the guidance entitled ``Guidance on \n        Procedures for the Provision of Marijuana for Medical \n        Research'' (issued on May 21, 1999); or\n            (2) create an additional review of scientific protocols \n        that is only conducted for research on marijuana other than the \n        review of research protocols performed at the request of a \n        researcher conducting nonhuman research that is not federally \n        funded, in accordance with section 303(f)(3)(A)(ii)(II) of the \n        Controlled Substances Act (21 U.S.C. 823(f)(3)(A)(ii)(II)), as \n        amended by section 3.\n\nSEC. 6. CONSIDERATION OF RESULTS OF RESEARCH.\n\n    Immediately upon the approval by the Food and Drug Administration \nof an application for a marijuana-based drug under section 505 of the \nFederal Food, Drug, and Cosmetic Act (21 U.S.C. 355), and (irrespective \nof whether any such approval is granted) not later than the date that \nis 5 years after the date of enactment of this Act, the Secretary of \nHealth and Human Services shall--\n            (1) conduct a review of existing medical and other research \n        with respect to marijuana;\n            (2) submit a report to the Congress on the results of such \n        review; and\n            (3) include in such report whether, taking into \n        consideration the factors listed in section 201(c) of the \n        Controlled Substances Act (21 U.S.C. 811(c)), as well as any \n        potential for medical benefits, any gaps in research, and any \n        impacts of Federal restrictions and policy on research, \n        marijuana should be transferred to a schedule other than \n        schedule I (if marijuana has not been so transferred already).\n\nSEC. 7. NO PRODUCTION QUOTAS FOR MARIJUANA GROWN FOR LEGITIMATE, \n              MEDICAL RESEARCH.\n\n    Section 306 of the Controlled Substances Act (21 U.S.C. 826) is \namended by adding at the end the following:\n    ``(i) The Attorney General may only establish a quota for \nproduction of marijuana that is manufactured and distributed in \naccordance with the Medical Marijuana Research Act of 2016 that meets \nthe changing medical, scientific, and industrial needs for \nmarijuana.''.\n\nSEC. 8. ARTICLE 28 OF THE SINGLE CONVENTION ON NARCOTIC DRUGS.\n\n    Article 28 of the Single Convention on Narcotic Drugs shall not be \nconstrued to prohibit, or impose additional restrictions upon, research \ninvolving marijuana, or the manufacture, distribution, or dispensing of \nmarijuana, that is conducted in accordance with the Controlled \nSubstances Act (21 U.S.C. 801 et seq.), this Act, and the amendments \nmade by this Act.\n\nSEC. 9. NO INTERFERENCE BY DEPARTMENT OF JUSTICE.\n\n    The Attorney General of the United States, and any officer or \nemployee of the Department of Justice, shall not interfere with the \nproduction, distribution, and sale of marijuana in accordance with this \nAct and the amendments made by this Act.\n\nSEC. 10. DEFINITION.\n\n    In this Act, the term ``marijuana'' has the meaning given to that \nterm in section 102 of the Controlled Substances Act (21 U.S.C. 802)."
}